Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
PharmaEssentia
PharmaEssentia
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Besremi
Ropeginterferon alfa-2b
2021-11-12
Polycythemia vera
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ropeginterferon alfa-2b
chronic hepatitis
,
healthy volunteers/patients
,
t-cell lymphoma cutaneous
,
neoplasms
,
hepatitis
,
hepatitis a
,
thrombocytosis
,
hepatitis d
,
coinfection
,
hepatocellular carcinoma
,
liver neoplasms
,
myelomonocytic leukemia chronic
,
leukemia myeloid chronic atypical bcr-abl negative
,
myelodysplastic-myeloproliferative diseases
,
polycythemia
,
chronic hepatitis b
,
hepatitis c
,
chronic hepatitis c
,
essential thrombocythemia
,
primary myelofibrosis
,
infections
,
communicable diseases
,
polycythemia vera
,
myeloproliferative disorders
,
hepatitis b
,
herpesviridae infections
Gilvetmab
neoplasms
,
neoplasm metastasis
,
melanoma
,
recurrence
,
squamous cell carcinoma
,
squamous cell neoplasms
,
carcinoma
,
lymphoma
,
squamous cell carcinoma of head and neck
,
basal cell carcinoma
,
basal cell neoplasms
,
colorectal neoplasms
,
hepatocellular carcinoma
,
stomach neoplasms
,
liver neoplasms
,
esophageal squamous cell carcinoma
,
hodgkin disease
,
uveal neoplasms
,
uveal melanoma
,
non-small-cell lung carcinoma
,
lung neoplasms
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use